Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)GlobeNewsWire • 02/24/26
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisGlobeNewsWire • 02/24/26
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)GlobeNewsWire • 02/19/26
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & SellsSeeking Alpha • 02/13/26
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating AllergyGlobeNewsWire • 02/10/26
These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 ResultsBenzinga • 02/02/26
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal DiseasesGlobeNewsWire • 02/02/26
Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 01/30/26
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New FactoryBenzinga • 01/30/26
Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares FellInvestors Business Daily • 01/30/26
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewsWire • 01/30/26
Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallBenzinga • 01/30/26
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings?Zacks Investment Research • 01/28/26
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 01/23/26